Primary Application
For what
Blood and Cardiovascular
Immune and Lymphatic
Integumentary
Mitochondrial and Energy Production
Source
Allopathy
For whom
People
All Trans Retinoic Acid (ATRA) is FDA approved in the treatment of promyelocytic leukemia. ATRA is a strong differentiating agent. As such, ATRA has potential as a therapy in a number of cancers, especially in the context of IC medicines. ATRA binds to retinoic acid receptors, and subsequently activates DNA transcription activity to move immature (e.g. malignant) cells toward normal maturation. Consider the use of ATRA in cases of cancer and precancerous lesions, including polyps, actinic keratosis, and others.
Similar ICs
325
46.4 k
12
1.36 k
178
64.7 k
187
127 k
9
477
408
56.3 k
493
153 k
29
736
127
38.3 k
176
58.1 k
Please select language
Select